{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T20:33:31Z","timestamp":1785530011340,"version":"3.56.0"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:p>\n                    Human papillomavirus (HPV)-independent oropharyngeal squamous cell carcinoma (OPSCC) is an aggressive cancer without established molecular prognosis.\n                    <jats:italic toggle=\"yes\">CDKN2A<\/jats:italic>\n                    (encoding p16) deletion is a common genetic event in HPV-independent OPSCC.\n                    <jats:italic toggle=\"yes\">CDKN2A<\/jats:italic>\n                    homozygous deletion is recognized as a poor prognostic factor in various tumors, such as gliomas, and methylthioadenosine phosphorylase (MTAP) immunostaining serves as a surrogate marker for it. Because MTAP is related to the methionine salvage pathway, various cancer cell lines with\n                    <jats:italic toggle=\"yes\">MTAP<\/jats:italic>\n                    deletion have been reported to exhibit increased sensitivity to the pyrimidine analog 5-fluorouracil (5-FU). This study aimed to clarify the prognostic effect of the expressions and homozygous deletions of\n                    <jats:italic toggle=\"yes\">CDKN2A<\/jats:italic>\n                    (\n                    <jats:italic toggle=\"yes\">p16<\/jats:italic>\n                    ) and\n                    <jats:italic toggle=\"yes\">MTAP<\/jats:italic>\n                    in 177 patients with OPSCC (106 HPV-positive and 71 HPV-negative) by immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH). MTAP loss by IHC was observed in 25.3% (16\/63) of HPV-negative\/p16-negative OPSCCs, and FISH confirmed homozygous deletions of both\n                    <jats:italic toggle=\"yes\">CDKN2A<\/jats:italic>\n                    and\n                    <jats:italic toggle=\"yes\">MTAP<\/jats:italic>\n                    . All HPV-negative\/p16-positive (n=8) and HPV-positive (n=106) OPSCCs did not exhibit MTAP deficiency. The prognosis of the HPV-negative\/MTAP\n                    <jats:italic toggle=\"yes\">-<\/jats:italic>\n                    loss group (n=16) was significantly better than that of the HPV-negative\/MTAP-retained group (n=47) and was as favorable as that of the HPV-positive group (n=106). A similar trend was confirmed in patients with HPV-negative OPSCC who received pyrimidine-based chemotherapy (n=46). MTAP deficiency is closely associated with homozygous\n                    <jats:italic toggle=\"yes\">CDKN2A<\/jats:italic>\n                    and\n                    <jats:italic toggle=\"yes\">MTAP<\/jats:italic>\n                    deletions in HPV-negative\/p16-negative OPSCCs. Furthermore, MTAP loss may be a favorable prognostic factor in HPV-negative OPSCC, and this paradoxical phenomenon might be explained by the enhanced efficacy of chemotherapy with pyrimidine analogs.\n                  <\/jats:p>","DOI":"10.1097\/pas.0000000000002482","type":"journal-article","created":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T05:00:41Z","timestamp":1762491641000},"page":"147-155","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["MTAP Loss Correlates With Favorable Prognosis in HPV-independent, p16-negative Oropharyngeal Squamous Cell Carcinoma"],"prefix":"10.1097","volume":"50","author":[{"given":"Hirotaka","family":"Hara","sequence":"first","affiliation":[{"name":"Anatomic Pathology"},{"name":"Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan"},{"name":"Department of Pathology and Oncology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidetaka","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Pathology and Oncology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryosuke","family":"Kuga","sequence":"additional","affiliation":[{"name":"Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rina","family":"Jiromaru","sequence":"additional","affiliation":[{"name":"Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeo","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Anatomic Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Midori","family":"Taniguchi","sequence":"additional","affiliation":[{"name":"Anatomic Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomomi","family":"Manako","sequence":"additional","affiliation":[{"name":"Anatomic Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Nakagawa","sequence":"additional","affiliation":[{"name":"Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinao","family":"Oda","sequence":"additional","affiliation":[{"name":"Anatomic Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,11,7]]},"reference":[{"key":"R1-20260113","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa0912217","article-title":"Human papillomavirus and survival of patients with oropharyngeal cancer","volume":"363","author":"Ang","year":"2010","journal-title":"N Engl J Med"},{"key":"R2-20260113","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1111\/his.14337","article-title":"p16 overexpression and Rb loss correlate with high-risk HPV infection in oropharyngeal squamous cell carcinoma","volume":"79","author":"Jiromaru","year":"2021","journal-title":"Histopathology"},{"key":"R3-20260113","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1002\/hed.27019","article-title":"Treatment de-escalation for HPV+ oropharyngeal cancer: a systematic review and meta-analysis","volume":"44","author":"Petrelli","year":"2022","journal-title":"Head Neck"},{"key":"R4-20260113","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/nature14129","article-title":"Comprehensive genomic characterization of head and neck squamous cell carcinomas","volume":"517","year":"2015","journal-title":"Nature"},{"key":"R5-20260113","doi-asserted-by":"crossref","first-page":"915","DOI":"10.21037\/atm-20-6264","article-title":"Molecular landscape of head and neck cancer and implications for therapy","volume":"9","author":"Farah","year":"2021","journal-title":"Ann Transl Med"},{"key":"R6-20260113","doi-asserted-by":"crossref","first-page":"3152","DOI":"10.1002\/ijc.32412","article-title":"Identification of prognostic molecular biomarkers in 157 HPV-positive and HPV-negative squamous cell carcinomas of the oropharynx","volume":"145","author":"Dogan","year":"2019","journal-title":"Int J Cancer"},{"key":"R7-20260113","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1002\/jcb.25592","article-title":"TP53 mutations in head and neck squamous cell carcinoma and their impact on disease progression and treatment response","volume":"117","author":"Zhou","year":"2016","journal-title":"J Cell Biochem"},{"key":"R8-20260113","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3389\/fonc.2018.00095","article-title":"CDKN2A copy number loss is an independent prognostic factor in HPV-negative head and neck squamous cell carcinoma","volume":"8","author":"Chen","year":"2018","journal-title":"Front Oncol"},{"key":"R9-20260113","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0968-0004(98)01236-5","article-title":"The INK4a\/ARF tumor suppressor: one gene\u2014two products\u2014two pathways","volume":"23","author":"Chin","year":"1998","journal-title":"Trends Biochem Sci"},{"key":"R10-20260113","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1038\/s41379-020-00701-w","article-title":"Utility of methylthioadenosine phosphorylase immunohistochemical deficiency as a surrogate for CDKN2A homozygous deletion in the assessment of adult-type infiltrating astrocytoma","volume":"34","author":"Satomi","year":"2021","journal-title":"Mod Pathol"},{"key":"R11-20260113","doi-asserted-by":"crossref","first-page":"4025","DOI":"10.1158\/1078-0432.CCR-21-0575","article-title":"CDKN2A alterations and response to immunotherapy in solid tumors","volume":"27","author":"Adib","year":"2021","journal-title":"Clin Cancer Res"},{"key":"R12-20260113","doi-asserted-by":"crossref","first-page":"vdaa126","DOI":"10.1093\/noajnl\/vdaa126","article-title":"Prognostic impact of CDKN2A\/B deletion, TERT mutation, and EGFR amplification on histological and molecular IDH-wildtype glioblastoma","volume":"2","author":"Ma","year":"2020","journal-title":"Neuro Oncol Adv"},{"key":"R13-20260113","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.euo.2021.10.006","article-title":"Integrative clinical and genomic characterization of MTAP-deficient metastatic urothelial cancer","volume":"6","author":"Alhalabi","year":"2023","journal-title":"Eur Urol Oncol"},{"key":"R14-20260113","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1093\/neuonc\/noz126.000","article-title":"CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas","volume":"21","author":"Appay","year":"2019","journal-title":"Neuro Oncol"},{"key":"R15-20260113","doi-asserted-by":"crossref","first-page":"vdae069","DOI":"10.1093\/noajnl\/vdae069","article-title":"Hemizygous deletion of cyclin-dependent kinase inhibitor 2A\/B with p16 immuno-negative and methylthioadenosine phosphorylase retention predicts poor prognosis in IDH-mutant adult glioma","volume":"6","author":"Otsuji","year":"2024","journal-title":"Neuro Oncol Adv"},{"key":"R16-20260113","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/s41379-019-0310-0","article-title":"MTAP immunohistochemistry is an accurate and reproducible surrogate for CDKN2A fluorescence in situ hybridization in diagnosis of malignant pleural mesothelioma","volume":"33","author":"Chapel","year":"2020","journal-title":"Mod Pathol"},{"key":"R17-20260113","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/0165-4608(95)00157-3","article-title":"Codeletion of the genes for p16INK4, methylthioadenosine phosphorylase, interferon-alpha1, interferon-beta1, and other 9p21 markers in human malignant cell lines","volume":"86","author":"Zhang","year":"1996","journal-title":"Cancer Genet Cytogenet"},{"key":"R18-20260113","doi-asserted-by":"crossref","first-page":"e5735","DOI":"10.1371\/journal.pone.0005735","article-title":"Selective killing of tumors deficient in methylthioadenosine phosphorylase: a novel strategy","volume":"4","author":"Lubin","year":"2009","journal-title":"PLoS One"},{"key":"R19-20260113","doi-asserted-by":"crossref","first-page":"e0145647","DOI":"10.1371\/journal.pone.0145647","article-title":"Characterization of MTAP gene expression in breast cancer patients and cell lines","volume":"11","author":"Oliveira","year":"2016","journal-title":"PLoS One"},{"key":"R20-20260113","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.4161\/cbt.21115","article-title":"Increasing the therapeutic index of 5-fluorouracil and 6-thioguanine by targeting loss of MTAP in tumor cells","volume":"13","author":"Tang","year":"2012","journal-title":"Cancer Biol Ther"},{"key":"R21-20260113","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/j.annonc.2024.08.2339","article-title":"First-in-human study of AMG 193, an MTA-cooperative PRMT5 inhibitor, in patients with MTAP-deleted solid tumors: results from phase I dose exploration","volume":"35","author":"Rodon","year":"2024","journal-title":"Ann Oncol"},{"key":"R22-20260113","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1158\/2159-8290.CD-24-0887","article-title":"AMG 193, a clinical stage MTA-cooperative PRMT5 inhibitor, drives antitumor activity preclinically and in patients with MTAP-deleted cancers","volume":"15","author":"Belmontes","year":"2025","journal-title":"Cancer Discov"},{"key":"R23-20260113","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1097\/PAS.0000000000002086","article-title":"HPV infection in squamous cell carcinoma of the hypopharynx, larynx, and oropharynx with multisite involvement","volume":"47","author":"Kuga","year":"2023","journal-title":"Am J Surg Pathol"},{"key":"R26-20260113","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/jnen\/nlab127","article-title":"Correlation of MTAP immunohistochemistry with CDKN2A status assessed by fluorescence in situ hybridization and clinicopathological features in CNS WHO grade 2 and 3 meningiomas: A single center cohort study","volume":"81","author":"Sasaki","year":"2022","journal-title":"J Neuropathol Exp Neurol"},{"key":"R27-20260113","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"R28-20260113","doi-asserted-by":"crossref","first-page":"e70012","DOI":"10.1002\/2056-4538.70012","article-title":"Loss of MTAP expression is strongly linked to homozygous 9p21 deletion, unfavorable tumor phenotype, and noninflamed microenvironment in urothelial bladder cancer","volume":"11","author":"Gorbokon","year":"2025","journal-title":"J Pathol Clin Res"},{"key":"R29-20260113","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1007\/s10120-015-0536-6","article-title":"Development of an S-1 dosage formula based on renal function by a prospective pharmacokinetic study","volume":"19","author":"Booka","year":"2016","journal-title":"Gastric Cancer"},{"key":"R30-20260113","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1038\/sj.bjc.6601335","article-title":"Both gene expression for orotate phosphoribosyltransferase and its ratio to dihydropyrimidine dehydrogenase influence outcome following fluoropyrimidine-based chemotherapy for metastatic colorectal cancer","volume":"89","author":"Ichikawa","year":"2003","journal-title":"Br J Cancer"},{"key":"R31-20260113","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.molcel.2016.11.003","article-title":"Arginine methylation: The coming of age","volume":"65","author":"Blanc","year":"2017","journal-title":"Mol Cell"},{"key":"R32-20260113","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/s41598-020-57812-2","article-title":"MTAP-deficiency could predict better treatment response in advanced lung adenocarcinoma patients initially treated with pemetrexed-platinum chemotherapy and bevacizumab","volume":"10","author":"Jing","year":"2020","journal-title":"Sci Rep"}],"container-title":["American Journal of Surgical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PAS.0000000000002482","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T06:00:13Z","timestamp":1768284013000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PAS.0000000000002482"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,7]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/pas.0000000000002482","relation":{},"ISSN":["0147-5185","1532-0979"],"issn-type":[{"value":"0147-5185","type":"print"},{"value":"1532-0979","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,7]]}}}